Key facts
- This page summarizes James R. Kasinger's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 14 Mar 2023, 17:45.
James R. Kasinger - 10 Mar 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- General Counsel and Secretary
- Issuer ticker
- CRSP
- Reported as of
- 10 Mar 2023
- Net transaction value
- -$99,622
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2023, 17:45:39 UTC
- Prior SEC filing
- 22 Feb 2023
- Next SEC filing
- 17 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James R. Kasinger filed Form 4 for CRISPR Therapeutics AG (CRSP) on 14 Mar 2023.
Change
- Previous filing in this sequence was filed on 22 Feb 2023.
- Current net transaction value: -$99,622.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRSP
transaction
Common Shares
Options Exercise
- Transaction value
- Shares
- +2,833
- Change %
- +5.4%
- Price
- Shares after
- 54,899
- Date
- 10 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
CRSP
transaction
Common Shares
Tax liability
- Transaction value
- $55,451
- Shares
- -1,283
- Change %
- -2.3%
- Price
- $43.22
- Shares after
- 53,616
- Date
- 13 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
CRSP
transaction
Common Shares
Options Exercise
- Transaction value
- Shares
- +2,250
- Change %
- +4.2%
- Price
- Shares after
- 55,866
- Date
- 11 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
CRSP
transaction
Common Shares
Tax liability
- Transaction value
- $44,171
- Shares
- -1,022
- Change %
- -1.8%
- Price
- $43.22
- Shares after
- 54,844
- Date
- 13 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -2,833
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 2,833
- Exercise price
- Footnotes
- F1, F3
CRSP
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 10 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 40,000
- Exercise price
- $43.22
- Footnotes
- F4
CRSP
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +22,000
- Change %
- Price
- $0.000000
- Shares after
- 22,000
- Date
- 10 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 22,000
- Exercise price
- Footnotes
- F1, F5
CRSP
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -2,250
- Change %
- -33%
- Price
- Shares after
- 4,500
- Date
- 11 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 2,250
- Exercise price
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Footnote F2
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Footnote F3
This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
Footnote F4
This option was granted on March 10, 2023 with respect to 40,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023.
Footnote F5
This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
Footnote F6
This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.